Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New hope for vaccine to fight rheumatoid arthritis, other autoimmune diseases

29.10.2002


Promising animal test results that could lead to a vaccine to fight rheumatoid arthritis, multiple sclerosis (MS) and other autoimmune diseases were announced by researchers at the Technion-Israel Institute of Technology. The vaccine reversed an arthritic-like disease in rats by mobilizing part of the immune system to protect joints under attack by other immune cells. The work was reported in two related papers in the September Journal of Immunology .



Autoimmune diseases, in which the immune system attacks the body’s own tissues, are among the most widespread of serious chronic diseases. In arthritis, immune cells attack the joints, while in MS, they attack the myelin sheaths of nerve cells.

Current treatments involve either steroids, which fight inflammation caused by the immune system attacks, or immuno-suppressant drugs, which depress immune system function generally. Both these approaches create serious side effects and can only slow, but not stop, the progress of the diseases. They are also effective mostly at very early stages of each disease.


The new approach, in contrast, tries to rally one part of the immune system to fight the part that is attacking the body’s tissues. "We know that, in autoimmune diseases, immune cells use chemical markers, called cytokines and chemokines, to induce inflammation that destroys organs," explains Dr. Nathan Karin of the Technion’s Department of Immunology and the research team leader. "These proteins also attract white blood cells that, in the case of arthritis, attack joint tissues, and in the case of MS, attack brain components. Our method helps the immune system itself interfere with this process."

In untreated arthritis, part of the immune system detects one of the chemical markers, called IP-10, recognizes that it is wrongly labeling the body’s own cells for attack, and destroys it. But while these naturally produced antibodies can slow, they cannot stop the progression of these diseases. In effect, there is a "civil war" within the immune system itself, with one part attacking and the other part protecting the body’s own cells. The new approach seeks to help the "good" part of the immune system in its fight with the "bad" or autoimmune part.

The researchers first identified that IP-10 is one of the specific proteins responsible for the progression of these diseases, and more importantly that the immune system tries to restrain the harmful activity of IP-10 by producing auto-antibodies against it. They then generated a special vaccine that amplifies the production of these beneficial antibodies. This vaccine rapidly suppressed experimentally induced rheumatoid arthritis and MS.

Dr. Karin hopes that for rheumatoid arthritis this approach will replace older treatments, which are extremely expensive and require many repeated immunizations, and that it will also open new horizons for the therapy of MS.

"We are hopeful that the gene-based vaccine will be much better, since only a few vaccinations are needed to train the immune system to destroy IP-10, and the rat results indicate that chronic relief may be possible," says Karin.

While the vaccine will interfere with IP-10 when the immune system uses it to label actual invaders such as bacteria, Karin does not expect this will cause serious side effects.

"There are some 50 chemicals that the immune system uses to label cells to be attacked," he points out. "Knocking out one will not seriously weaken the immune system’s response to infection or cancer. But in autoimmune diseases, where one part of the immune system is fighting another, eliminating IP-10 will shift the balance, giving the edge to the part that is protecting the body."

The next step is to move towards clinical tests of the vaccine in humans. Clinical tests are now planned for MS patients, and the group is negotiating with an as yet unnamed major U.S. pharmaceutical company.


The Technion-Israel Institute of Technology, known as "Israel’s MIT," is Israel’s leading scientific and technological center for applied research and education. It commands a worldwide reputation for its pioneering work in computer science, biotechnology, water-resource management, materials engineering, aerospace and medicine. Based in New York City, the American Technion Society (ATS) is the leading American organization supporting higher education in Israel.


Martha Molnar | EurekAlert!
Further information:
http://www.technion.ac.il/

More articles from Health and Medicine:

nachricht How prenatal maternal infections may affect genetic factors in Autism spectrum disorder
22.03.2017 | University of California - San Diego

nachricht Camouflage apples
22.03.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Pulverizing electronic waste is green, clean -- and cold

22.03.2017 | Materials Sciences

Astronomers hazard a ride in a 'drifting carousel' to understand pulsating stars

22.03.2017 | Physics and Astronomy

New gel-like coating beefs up the performance of lithium-sulfur batteries

22.03.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>